ADAMAS PHARMACEUTICALS INC's ticker is ADMS and the CUSIP is 00548A106. A total of 83 filers reported holding ADAMAS PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $630,000 | +45.5% | 128,347 | +56.3% | 0.00% | – |
| Q2 2021 | $433,000 | +5.9% | 82,127 | -3.7% | 0.00% | – |
| Q1 2021 | $409,000 | +7.3% | 85,255 | -3.2% | 0.00% | – |
| Q4 2020 | $381,000 | +67.8% | 88,051 | +59.2% | 0.00% | – |
| Q3 2020 | $227,000 | +530.6% | 55,314 | +294.9% | 0.00% | – |
| Q2 2020 | $36,000 | -84.4% | 14,006 | -82.5% | 0.00% | – |
| Q1 2020 | $231,000 | -24.3% | 79,913 | -0.7% | 0.00% | – |
| Q4 2019 | $305,000 | -27.7% | 80,449 | -2.5% | 0.00% | – |
| Q3 2019 | $422,000 | -19.5% | 82,542 | -2.4% | 0.00% | – |
| Q2 2019 | $524,000 | -17.5% | 84,548 | -5.4% | 0.00% | – |
| Q1 2019 | $635,000 | -14.9% | 89,372 | +2.2% | 0.00% | – |
| Q4 2018 | $746,000 | -85.0% | 87,406 | -64.9% | 0.00% | -100.0% |
| Q3 2018 | $4,981,000 | -21.7% | 248,742 | +1.0% | 0.00% | -50.0% |
| Q2 2018 | $6,363,000 | +21.8% | 246,352 | +12.7% | 0.00% | +100.0% |
| Q1 2018 | $5,226,000 | +39.2% | 218,656 | +97.3% | 0.00% | 0.0% |
| Q4 2017 | $3,755,000 | +189.5% | 110,821 | +80.9% | 0.00% | – |
| Q3 2017 | $1,297,000 | +17.2% | 61,273 | -3.3% | 0.00% | – |
| Q2 2017 | $1,107,000 | -3.9% | 63,337 | -3.8% | 0.00% | – |
| Q1 2017 | $1,152,000 | +6.1% | 65,830 | +2.4% | 0.00% | – |
| Q4 2016 | $1,086,000 | +16.1% | 64,267 | +12.9% | 0.00% | – |
| Q3 2016 | $935,000 | +2.5% | 56,933 | -5.6% | 0.00% | – |
| Q2 2016 | $912,000 | +27.6% | 60,282 | +21.8% | 0.00% | – |
| Q1 2016 | $715,000 | -58.8% | 49,480 | -19.1% | 0.00% | -100.0% |
| Q4 2015 | $1,734,000 | +85.1% | 61,199 | +9.4% | 0.00% | – |
| Q3 2015 | $937,000 | -34.8% | 55,951 | +2.0% | 0.00% | – |
| Q2 2015 | $1,438,000 | +140.9% | 54,880 | +60.6% | 0.00% | – |
| Q1 2015 | $597,000 | +7.2% | 34,164 | +6.4% | 0.00% | – |
| Q4 2014 | $557,000 | – | 32,095 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,601,351 | $43,963,000 | 9.03% |
| Granite Point Capital Management, L.P. | 256,031 | $4,327,000 | 3.45% |
| Opaleye Management Inc. | 285,000 | $4,817,000 | 2.84% |
| Brenner West Capital Advisors | 1,221,463 | $20,643,000 | 2.28% |
| ARMISTICE CAPITAL, LLC | 536,000 | $9,058,000 | 2.14% |
| NEXTHERA CAPITAL LP | 151,670 | $2,563,000 | 1.50% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 185,234 | $3,130,000 | 1.41% |
| Cheyne Capital Management (UK) LLP | 144,765 | $2,448,000 | 1.38% |
| SPHERA FUNDS MANAGEMENT LTD. | 270,000 | $4,563,000 | 1.16% |
| Mosaic Family Wealth, LLC | 123,314 | $2,084,000 | 0.96% |